Technical Articles

This article focuses on the central role of the ALK7 receptor in the NHBE/ALK7 pathway, systematically elaborating its molecular characteristics as a type I receptor of the TGF-β receptor superfamily and the assembly mechanism of the tetrameric receptor complex, analyzing the signaling logic by which Activin E negatively regulates adipocyte lipolysis via the ALK7-SMAD2/3 axis, and exploring the differences between two small nucleic acid drug approaches—targeting ACVR1C to silence ALK7 and targeting INHBE to silence Activin E—in terms of tissue delivery and signaling coverage.